Wall Street analyst estimates for Stevanato Group S.p.A. (STVN): consensus price target and buy/hold/sell recommendations.
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (−2 sell to +2 buy) | 0.62 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $0.18 | ||
| 2026-08-04 | $0.16 | $0.14 | +10.5% |
| 2026-05-07 | $0.13 | $0.12 | +8.3% |
| 2026-03-04 | $0.21 | $0.20 | +5.0% |
| 2025-11-06 | $0.16 | $0.14 | +14.3% |
| 2025-08-05 | $0.12 | $0.11 | +9.1% |
| 2025-05-08 | $0.11 | $0.10 | +10.0% |
| 2025-03-06 | $0.20 | $0.20 | +0.0% |
Valuation Ratios
| P/E Ratio | 36.34 |
| Price / Book | 3.07 |
| EV / EBITDA | 17.30 |
| Dividend Yield | 0.32% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 536.5M EUR | 662.0M EUR | 843.9M EUR | 983.7M EUR | 1.09B EUR | 1.10B EUR | 1.14B EUR |
| Cost of Revenue | 398.5M EUR | 467.9M EUR | 578.5M EUR | 663.9M EUR | 745.5M EUR | 801.7M EUR | 809.2M EUR |
| Gross Profit | 138.0M EUR | 194.2M EUR | 265.4M EUR | 319.8M EUR | 339.9M EUR | 302.3M EUR | 330.3M EUR |
| Research & Development | 7.8M EUR | 17.4M EUR | 29.6M EUR | 34.4M EUR | 35.7M EUR | 31.7M EUR | 24.4M EUR |
| Selling, General & Admin | 76.7M EUR | 78.9M EUR | 83.0M EUR | 111.8M EUR | 113.9M EUR | 118.6M EUR | 122.9M EUR |
| Operating Expenses | 75.8M EUR | 91.1M EUR | 103.2M EUR | 127.4M EUR | 139.2M EUR | 141.2M EUR | 147.2M EUR |
| Operating Income | 62.2M EUR | 103.1M EUR | 162.2M EUR | 192.4M EUR | 200.7M EUR | 161.1M EUR | 183.1M EUR |
| EBITDA | 106.5M EUR | 156.4M EUR | 226.9M EUR | 256.4M EUR | 272.3M EUR | 247.8M EUR | 292.0M EUR |
| Interest Expense | 5.3M EUR | 6.8M EUR | 4.9M EUR | 3.9M EUR | 4.3M EUR | 6.9M EUR | 21.8M EUR |
| Pre-tax Income | 54.7M EUR | 96.3M EUR | 165.7M EUR | 187.6M EUR | 189.6M EUR | 160.3M EUR | 181.6M EUR |
| Income Tax | 16.0M EUR | 17.7M EUR | 31.4M EUR | 44.6M EUR | 43.9M EUR | 42.5M EUR | 47.4M EUR |
| Net Income | 39.2M EUR | 78.5M EUR | 134.3M EUR | 142.8M EUR | 145.6M EUR | 117.8M EUR | 134.3M EUR |
| EPS | $0.15 | $0.28 | $0.53 | $0.53 | $0.55 | $0.43 | $0.49 |
| EPS (Diluted) | $0.15 | $0.28 | $0.53 | $0.53 | $0.55 | $0.43 | $0.49 |
| Shares Outstanding (Diluted) | 264.7 M | 264.7 M | 264.7 M | 264.7 M | 265.0 M | 272.9 M | 273.0 M |
Price
| Price | $19.43 (closing price, October 28, 2026) |
| Market Cap | $5.3B |
| Exchange | NYSE |
| Country | IT |
Related companies: AXSM · BTSG · MMSI · ATR · BLCO · AVTR
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of STVN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks